These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 216556)

  • 21. A phase III study in lung carcinoma comparing hexamethyl-melamine (NSC 13875) to dibromodulcitol (NSC 104800) 1,2.
    Wilson WL; Ryzin JV; Weiss AJ; Frelick RW; Moss SE
    Oncology; 1975; 31(5-6):293-309. PubMed ID: 174041
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Podophyllotoxins for brain metastases of small cell lung cancer.
    Haaxma-Reiche H; Berendsen HH; Postmus PE
    J Neurooncol; 1988 Nov; 6(3):231-2. PubMed ID: 2852221
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [A phase II study of NK171 (etoposide)].
    Kimura K; Niitani H
    Gan To Kagaku Ryoho; 1985 Oct; 12(10):2011-7. PubMed ID: 2996442
    [TBL] [Abstract][Full Text] [Related]  

  • 24. MACC (methotrexate, adriamycin, cyclophosphamide and CCNU) in advanced lung cancer.
    Chahinian AP; Mandel EM; Holland JF; Jaffrey IS; Teirstein AS
    Cancer; 1979 May; 43(5):1590-7. PubMed ID: 221093
    [No Abstract]   [Full Text] [Related]  

  • 25. Unexpected high toxicity in a phase II study of teniposide (VM-26) in elderly patients with untreated small cell lung cancer (SCLC).
    Cerny T; Pedrazzini A; Joss RA; Brunner KW
    Eur J Cancer Clin Oncol; 1988 Nov; 24(11):1791-4. PubMed ID: 2850194
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Evaluation of an intermittent schedule of mitolactol in advanced non-small cell lung cancer.
    Eagan RT; Frytak S; Nichols WC; Ingle JN; Creagan ET; Kvols LK; Coles DT
    Cancer Treat Rep; 1981; 65(11-12):1099-1101. PubMed ID: 6271397
    [No Abstract]   [Full Text] [Related]  

  • 27. Trial of 1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea (CCNU; NSC-79037) in advanced bronchogenic carcinoma 1,2,3.
    Stolinsky DC; Bull FE; Pajak TF; Bateman JR
    Oncology; 1975; 31(5-6):288-92. PubMed ID: 174040
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Teniposide in recurrent or advanced cervical carcinoma: a phase II trial in patients not previously treated with cytotoxic therapy.
    Pfeiffer P; Cold S; Bertelsen K; Panduro J; Sandberg E; Rose C
    Gynecol Oncol; 1990 May; 37(2):230-3. PubMed ID: 2344968
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Teniposide (VM-26) in patients with advanced refractory ovarian cancer: a phase II study of the Netherlands Joint Study Group for Ovarian Cancer.
    van der Burg ME; ten Bokkel Huinink WW; Vriesendorp R; van Oosterom AT; Neijt JP; Vermorken JB; van Putten WL; Kooiman A
    Eur J Cancer Clin Oncol; 1987 Jul; 23(7):997-8. PubMed ID: 3666002
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [New antineoplastic drugs of the podophyllotoxin derivative group].
    Robak T; Płuzańska A
    Pol Tyg Lek; 1983 Jan; 38(1):27-30. PubMed ID: 6346283
    [No Abstract]   [Full Text] [Related]  

  • 31. Phase II evaluation of dianhydrogalactitol in lung cancer: a Southwest Oncology Group Study.
    Haas CD; Baker L; Thigpen T
    Cancer Treat Rep; 1981; 65(1-2):115-7. PubMed ID: 6261943
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [A phase II study of oral VP-16 in primary lung cancer].
    Matsui Y; Ohshima S; Kado M; Nakayama M; Shimokata K; Sakai S; Ito F; Chikata E; Hara K; Kanda T
    Gan To Kagaku Ryoho; 1985 Sep; 12(9):1801-7. PubMed ID: 2994576
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Teniposide for brain metastases of small-cell lung cancer: a phase II study. European Organization for Research and Treatment of Cancer Lung Cancer Cooperative Group.
    Postmus PE; Smit EF; Haaxma-Reiche H; van Zandwijk N; Ardizzoni A; Quoix E; Kirkpatrick A; Sahmoud T; Giaccone G
    J Clin Oncol; 1995 Mar; 13(3):660-5. PubMed ID: 7884426
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Use of VM-26 as a single agent in the treatment of renal carcinoma.
    Hire EA; Samson MK; Fraile RJ; Baker LH
    Cancer Clin Trials; 1979; 2(4):293-5. PubMed ID: 394865
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Phase II clinical trial of weekly administration of VP-16-213 in small cell bronchogenic carcinoma.
    Cohen MH; Broder LE; Fossieck BE; Ihde DC; Minna JD
    Cancer Treat Rep; 1977; 61(3):489-90. PubMed ID: 194694
    [No Abstract]   [Full Text] [Related]  

  • 36. Treatment strategies in relation to drug action.
    Muggia FM; McVie G
    NCI Monogr; 1987; (4):129-33. PubMed ID: 2819724
    [No Abstract]   [Full Text] [Related]  

  • 37. Treatment of extensive small cell lung cancer with carboplatin and teniposide.
    Sørensen BT; Nielsen K; Steenholdt S; Schultz H; Jakobsen A
    Eur J Cancer; 1991; 27(9):1109-12. PubMed ID: 1659851
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Pharmacokinetics of teniposide in patients with ovarian cancer.
    D'Incalci M; Rossi C; Sessa C; Urso R; Zucchetti M; Farina P; Mangioni C
    Cancer Treat Rep; 1985 Jan; 69(1):73-7. PubMed ID: 3967261
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The podophyllotoxin derivatives VP16-213 and VM26.
    Issell BF
    Cancer Chemother Pharmacol; 1982; 7(2-3):73-80. PubMed ID: 7044593
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Phase II evaluation of VM-26 in patients with metastatic transitional cell carcinoma of the urinary tract: an Eastern Cooperative Oncology Group study.
    Qazi R; Elson P; Khandekar JD
    Cancer Treat Rep; 1982 Feb; 66(2):405-6. PubMed ID: 7055823
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.